NEXT GENERATION APPROACH IN ADVANCED PROSTATE CANCER. MEET THE PROFESSOR WITH ELENA CASTRO

• FRANCESCO CARROZZA· DOTTORE
• VINCENZA CONTEDUCA· PROFESSORE

• NICOLE BRIGHI· RELATORE
• FRANCESCO CARROZZA· RELATORE
• ELENA CASTRO· RELATORE
• VINCENZA CONTEDUCA· RELATORE
• STEFANIA DI GIROLAMO· RELATORE
• SIMONA SCODES· RELATORE
• STEFANO TAMBERI· RELATORE
• SALVATORE GIUSEPPE VOCE· RELATORE

Ragione sociale

MI&T SRL

Stato accreditamento

STANDARD - 1° rinnovo

Di sistema

Tailored strategies for patients with brca or hrr mutations are increasingly important. Parp inhibitors like olaparib and rucaparib offer targeted treatment options, particularly for patients harboring these mutations. Understanding the hrr status allows for a more refined therapeutic approach, guiding the use of parp inhibitors either as monotherapy or in combination with other treatments. The integration of these advanced approaches, from precision medicine to radiometabolic options, reflects the shift toward personalized, evidence-based care. This multi-modal strategy maximizes therapeutic outcomes while minimizing unnecessary toxicity, paving the way for more effective and patient-specific management of advanced prostate cancer. This event addresses all these topics to enhance knowledge and experience regarding innovative strategies for managing prostate cancer.

#2Linee guida - protocolli - procedure

Area: Obiettivi formativi tecnico-professionali

Partecipanti max

100

Verifica presenza

Firma Di Presenza

Verifica apprendimento

Questionario A Risposta Multipla